Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SGMT 
Sagimet Biosciences Inc. Series A Common Stock (SGMT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: SGMT (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.86
1 Year Target Price $27.86
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 141.82% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 239.36M USD | Price to earnings Ratio - | 1Y Target Price 27.86 |
Price to earnings Ratio - | 1Y Target Price 27.86 | ||
Volume (30-day avg) 7 | Beta 3.27 | 52 Weeks Range 1.73 - 11.41 | Updated Date 10/18/2025 |
52 Weeks Range 1.73 - 11.41 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.86 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.61% | Return on Equity (TTM) -37.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 107599648 | Price to Sales(TTM) 52.5 |
Enterprise Value 107599648 | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 31001109 | Shares Floating 22626577 |
Shares Outstanding 31001109 | Shares Floating 22626577 | ||
Percent Insiders 9.81 | Percent Institutions 29.16 |
Upturn AI SWOT
Sagimet Biosciences Inc. Series A Common Stock
Company Overview
History and Background
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for diseases, including non-alcoholic steatohepatitis (NASH) and acne. The company has developed a portfolio of proprietary fatty acid synthase (FASN) inhibitors.
Core Business Areas
- Drug Development: Developing and commercializing FASN inhibitors for NASH and acne.
- Clinical Trials: Conducting clinical trials to evaluate the efficacy and safety of its drug candidates.
Leadership and Structure
The company is led by a team with experience in drug development and commercialization. The organizational structure includes research, clinical development, and business operations departments.
Top Products and Market Share
Key Offerings
- Denifanstat: Denifanstat is Sagimet's lead drug candidate, a FASN inhibitor being developed for NASH. It's in Phase 2b clinical trials. NASH market has several competitors, including Madrigal Pharmaceuticals (MDGL) with resmetirom, and Viking Therapeutics (VKTX) with VK2809.
- TVB-3166: TVB-3166 is Sagimet's FASN inhibitor drug candidate being developed for acne. It's in Phase 2 clinical trials. Competitors for TVB-3166 include Cassiopea (CASSI) with Winlevi and Arcutis Biotherapeutics (ARQT) with Zoryve.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving. The NASH market is expected to grow significantly due to the rising prevalence of the disease. The acne market is also substantial with continous focus on innovative therapeutics.
Positioning
Sagimet is positioned as a company focused on developing innovative FASN inhibitors for NASH and acne. Its competitive advantage lies in its proprietary technology and clinical development expertise.
Total Addressable Market (TAM)
The NASH market is estimated to be in the tens of billions of dollars. Sagimet is positioned to capture a share of this market with successful clinical trials and commercialization of denifanstat. The acne market TAM is several billion dollars.
Upturn SWOT Analysis
Strengths
- Proprietary FASN inhibitor technology
- Experienced management team
- Promising clinical trial results for denifanstat
Weaknesses
- Limited commercialization experience
- Reliance on clinical trial success
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Favorable regulatory environment for NASH drugs
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Unfavorable regulatory changes
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- CASSI
- ARQT
Competitive Landscape
Sagimet faces competition from established pharmaceutical companies with greater resources. However, its proprietary technology and promising clinical data provide a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is currently based on progress in clinical trials and securing funding.
Future Projections: Future growth is dependent on the successful clinical development and commercialization of denifanstat and other drug candidates. Analyst projections are not readily available.
Recent Initiatives: Focusing on advancing Phase 2b clinical trials for denifanstat in NASH and Phase 2 for TVB-3166 in acne. Further capital fundraising to support operations.
Summary
Sagimet Biosciences is a clinical-stage biopharmaceutical company with a focus on NASH and acne. Its strengths lie in its proprietary FASN inhibitor technology and experienced management team. The company's success is highly dependent on the successful completion of clinical trials and subsequent commercialization. Sagimet needs to carefully manage its cash burn and navigate the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Sagimet Biosciences Inc. website
- SEC filings
- Industry reports
- Clinical trial data
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data are approximate and based on available information as of the current date. Ratings are subject to change based on new information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sagimet Biosciences Inc. Series A Common Stock
Exchange NASDAQ | Headquaters San Mateo, CA, United States | ||
IPO Launch date 2023-07-14 | CEO, President & Director Mr. David A. Happel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.sagimet.com |
Full time employees 14 | Website https://www.sagimet.com | ||
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.